title: [Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy].
abstract: The patient was a 58-year-old man who suffered from non-resectable gastric cancer, staged intraoperatively for peritoneal dissemination and paraaorta lymph node metastasis at another hospital in December 2002. He was initially treated with TS-1 as an outpatient. However, he was readmitted on March 4, 2003 for hematuria, general fatigue, jaundice and dyspnea. He was diagnosed with gastric cancer duodenum invasion, obstructive jaundice and lymphangitis carcinomatosa, and began weekly TXL as second-line chemotherapy on March 26. TXL (70 mg/ m2) was infused once a week for 3 weeks followed by a 1-week interval as one cycle. One week after the first infusion therapy, the jaundice and dyspnea were greatly improved. CT scan showed the lymphangitis carcinomatosa had disappeared and paraaorta lymph node metastasis was reduced to 60% after one cycle of the treatment. The toxic events were leukopenia (grade 1) and alopecia (grade 1).
authors.affiliation: Dept. of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.
authors.forename: Hirozumi
authors.initials: H
authors.lastname: Mizuiri
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshida
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Shimizu
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Tanabe
authors.forename: Junya
authors.initials: J
authors.lastname: Taomoto
authors.forename: Takahisa
authors.initials: T
authors.lastname: Suzuki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Wada
authors.forename: Jun
authors.initials: J
authors.lastname: Hihara
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004379:Duodenal Neoplasms / Q000473:pathology; D006801:Humans; D041781:Jaundice, Obstructive / Q000473:pathology; D007970:Leukopenia / Q000139:chemically induced; D008198:Lymph Nodes / Q000473:pathology*; D008205:Lymphangitis / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel